E7389

DRUG12 trials

Sponsors

Eisai Inc., Eisai Co., Ltd.

Conditions

Advanced Solid TumorsBladder CancerBreast CancerBreast NeoplasmsCancerProstate CancerSoft Tissue SarcomaUnspecified Adult Solid Tumor, Protocol Specific

Phase 1

Study of E7389 in Patients With Advanced Solid Tumors

CompletedNCT00069264

Eisai Inc.Advanced Solid Tumors

Start: 2003-09-30End: 2005-07-31Updated: 2011-12-20

Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors

CompletedNCT00069277

Eisai Inc.Cancer

Start: 2003-08-31End: 2005-04-30Updated: 2012-04-11

Phase I Clinical Study of E7389

CompletedNCT00326950

Eisai Co., Ltd.Cancer

Start: 2006-06-30End: 2008-02-29Updated: 2012-03-08

Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System

CompletedNCT00706095

Eisai Inc.Cancer

Start: 2008-02-29End: 2010-04-30Updated: 2012-03-27

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

TerminatedNCT01126749

Eisai Inc.Bladder Cancer

Start: 2010-04-16End: 2016-07-20Updated: 2022-02-28

An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function

CompletedNCT01418677

Eisai Inc.Unspecified Adult Solid Tumor, Protocol Specific

Start: 2011-10-31End: 2015-05-31Updated: 2016-05-17

A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer

CompletedNCT01432886

Eisai Co., Ltd.Breast Cancer

Start: 2011-10-31End: 2013-12-31Updated: 2016-10-07

Phase 2

A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

CompletedNCT00097721

Eisai Inc.Breast Neoplasms

Start: 2004-09-30End: 2006-11-30Updated: 2013-04-22

A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine

CompletedNCT00246090

Eisai Inc.Breast Cancer

Start: 2005-10-31End: 2007-09-30Updated: 2014-07-14

Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

CompletedNCT00278993

Eisai Inc.Prostate Cancer

Start: 2006-01-31End: 2008-01-31Updated: 2014-07-14

E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma

CompletedNCT00413192

Eisai Inc.Soft Tissue Sarcoma

Start: 2007-01-31End: 2013-02-28Updated: 2017-04-26

Phase 3

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

CompletedNCT00388726

Eisai Inc.Breast Cancer

Start: 2006-11-30End: 2013-06-30Updated: 2020-01-07

Related Papers

Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study

Breast Cancer Research and Treatment2024-04-064 citations

Clinical outcomes of patients with metastatic breast cancer treated with eribulin: A real-world evidence study from China.

Journal of Clinical Oncology2023-06-01

High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study

Breast Cancer2020-03-0571 citations

Economic evaluation of eribulin in the treatment of triple negative breast cancer in the United Kingdom

Annals of Oncology2018-10-01

Eribulin Mesylate Plus Pembrolizumab Shows Encouraging Efficacy in TNBC

Oncology Times2018-01-311 citations

Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.

2017-02-1624 citations

Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.

2016-05-1373 citations

"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy.

2015-12-0936 citations

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial

Breast Cancer Research and Treatment2015-11-1469 citations

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function

Cancer Chemotherapy and Pharmacology2015-10-0321 citations

Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).

Journal of Clinical Oncology2015-06-2035 citations

Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.

2014-09-2311 citations

Peripheral neuropathy (PN) in patients (pts) with metastatic breast cancer treated with eribulin: Resolution and association with efficacy.

Journal of Clinical Oncology2014-09-104 citations

Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled analysis by HER2 and ER status.

Journal of Clinical Oncology2014-09-101 citations

Pharmacokinetics (PK) of eribulin mesylate in cancer patients (pts) with normal and impaired renal function.

Journal of Clinical Oncology2014-05-205 citations

Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled analysis by HER2 and ER status.

Journal of Clinical Oncology2014-05-201 citations

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.

2011-09-19161 citations

Eribulin mesylate in patients with refractory cancers: a Phase I study.

2011-09-0254 citations

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

2011-03-02794 citations